Latest Listings And Ipos News

One Click Group Limited reported a 42% increase in registered users and a 26% rise in revenue to $4.9 million in Q4 2024, while preparing to launch its new superannuation product in 2025.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

Axel REE Limited reports a breakthrough in its Brazilian exploration with record high-grade rare earth and gallium assays at the Caladão Project, expanding the mineralised area significantly and securing funding to advance resource definition.

Lefroy Exploration Limited reported a modest net cash decrease in the December quarter, ending with $3.24 million in cash reserves and nearly four quarters of funding available. The company continues to invest heavily in exploration activities despite operating cash outflows.

Dragon Mountain Gold Limited reports promising drilling results at its Avalon Project and prepares for further exploration at Cawse, supported by a successful $670,000 capital raise and strategic board appointment.

Gas2Grid navigates regulatory headwinds in Australia by pursuing new petroleum ventures in the Philippines while contesting a significant legal claim in France. The company’s ASX suspension persists as it seeks to restore compliance through fresh contracts.

Brookside Energy Ltd delivered a standout quarter in Q4 2024, posting record production growth and a 667% jump in operating cash flow, while completing a major development project ahead of schedule and under budget.

Vintage Energy has launched a $2.1 million entitlement offer to fund a targeted production uplift program at its Odin and Vali gas fields, aiming to significantly increase gas output and cash flow in the near term.

IRIS Metals has completed key drilling programs at its South Dakota lithium projects and successfully raised $8 million, positioning itself to deliver its maiden mineral resource estimate for the Beecher Project in early 2025.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

ResMed Inc. posted a robust second quarter for fiscal year 2025, with revenue climbing 10% to $1.3 billion and operating profit soaring 52%, driven by strong demand for sleep and breathing health products and operational efficiencies.

St Barbara has secured A$100 million to fast-track its Simberi Sulphides project, aiming to bring forward production by up to five months, even as Q2 gold output fell short of expectations due to operational challenges.